Governors Lane’s Senti Biosciences Holdings SNTI Stock Holding History

Governors Lane’s Portfolio SNTI Stock Details SNTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-35,000	Closed	-$3.46M	–	189
2022 Q1	$3.46M	Hold	35,000	–	–	0.25%	113
2021 Q4	$3.45M	Hold	35,000	–	–	0.21%	133
2021 Q3	$3.48M	Hold	35,000	–	–	0.23%	107
2021 Q2	$3.48M	Buy	+35,000	New	+$3.49M	0.25%	98

Other funds holding SNTI

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Intel Corp Santa Clara, California $470M AUM 21.74% 1-Year Est. Return

FMN

Financial Management Network Mission Viejo, California $653M AUM 17.76% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Kingfisher Capital Charlotte, North Carolina $437M AUM 41.72% 1-Year Est. Return

Governors Lane's SNTI Position: Q2 2022 in Review

Governors Lane sold out of Senti Biosciences Holdings (SNTI) in Q2 2022, closing a stake of 35,000 shares — an estimated $3.46M sold.

Governors Lane first reported a position in SNTI in Q2 2021 and held it in 4 quarters. The position peaked at $3.48M in Q3 2021. 22 funds tracked by Wall St. Rank hold SNTI as of Q2 2022.

Governors Lane reported no remaining Senti Biosciences Holdings position as of Q2 2022 after selling out during the quarter.
Governors Lane sold 35,000 Senti Biosciences Holdings shares in Q2 2022, an estimated $3.46M.
Governors Lane first reported a position in Senti Biosciences Holdings in Q2 2021 and held it in 4 quarters.
Governors Lane's Senti Biosciences Holdings position peaked at $3.48M in Q3 2021.
22 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2022.

Based on Governors Lane's 13F filing for Q2 2022, filed 15 Aug 2022.